Nicotine modulates cognitive function in D-galactose-induced senescence in mice by Majdi, Alireza et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Nicotine modulates cognitive function in D-galactose-induced senescence in mice
Majdi, Alireza; Sadigh-Eteghad, Saeed; Talebi, Mahnaz; Farajdokht, Fereshteh; Erfani,
Marjan; Mahmoudi, Javad; Gjedde, Albert
Published in:
Frontiers in Aging Neuroscience
DOI:
10.3389/fnagi.2018.00194
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
Unspecified
Citation for published version (APA):
Majdi, A., Sadigh-Eteghad, S., Talebi, M., Farajdokht, F., Erfani, M., Mahmoudi, J., & Gjedde, A. (2018). Nicotine
modulates cognitive function in D-galactose-induced senescence in mice. Frontiers in Aging Neuroscience, 10,
[194]. https://doi.org/10.3389/fnagi.2018.00194
Download date: 03. Feb. 2020
ORIGINAL RESEARCH
published: 13 July 2018
doi: 10.3389/fnagi.2018.00194
Nicotine Modulates Cognitive
Function in D-Galactose-Induced
Senescence in Mice
Alireza Majdi1, Saeed Sadigh-Eteghad1*, Mahnaz Talebi1, Fereshteh Farajdokht1,
Marjan Erfani1, Javad Mahmoudi1 and Albert Gjedde1,2,3,4,5
1Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, 2Departments of Clinical Research and
Nuclear Medicine, Odense University Hospital, University of Southern Denmark, Odense, Denmark, 3Department of
Neuroscience, University of Copenhagen, Copenhagen, Denmark, 4Department of Neurology and Neurosurgery, McGill
University, Montreal, QC, Canada, 5Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore,
MD, United States
Edited by:
Ashok Kumar,
University of Florida, United States
Reviewed by:
Karolina Pytka,
Jagiellonian University, Poland
Paul E. Gold,
Syracuse University, United States
*Correspondence:
Saeed Sadigh-Eteghad
saeed.sadigetegad@gmail.com
Received: 20 December 2017
Accepted: 08 June 2018
Published: 13 July 2018
Citation:
Majdi A, Sadigh-Eteghad S, Talebi M,
Farajdokht F, Erfani M, Mahmoudi J
and Gjedde A (2018) Nicotine
Modulates Cognitive Function in
D-Galactose-Induced
Senescence in Mice.
Front. Aging Neurosci. 10:194.
doi: 10.3389/fnagi.2018.00194
Here, we tested the claim that nicotine attenuates the signs of brain dysfunction in the
model of brain aging induced by D-galactose (DGal) in mice. We administered nicotine
at doses of 0.1, 0.5 and 1 mg/kg by the subcutaneous (s.c.) or at 0.1 mg/kg by
the intranasal (i.n.) routes in mice that had received DGal at the dose of 500 mg/kg
subcutaneous (s.c.) for 6 weeks. We assessed animal withdrawal signs as the number
of presented somatic signs, thermal hyperalgesia, elevated plus maze (EPM) and open
field tests. We evaluated spatial memory and recognition with Barnes maze and novel
object recognition (NOR) tests. We tested brain tissue for reactive oxygen species (ROS),
mitochondrial membrane potential, caspase-3, Bax, Bcl-2, cytochrome C, brain-derived
neurotrophic factor and nerve growth factor levels. Nicotine administration in model
groups (0.5 mg/kg s.c. and 0.1 mg/kg i.n. doses) significantly attenuated impairment of
spatial and episodic memories in comparison to normal saline-received model group.
These doses also reduced mito-oxidative damage as well as apoptosis and raised
neurotrophic factors level in model groups in comparison to normal saline-received
model group. The 1 mg/kg s.c. dose nicotine revealed withdrawal signs compared
with the other nicotine-received groups. Nicotine at specific doses and routes has the
potential to attenuate age-related cognitive impairment, mito-oxidative damage, and
apoptosis. The doses raise neurotrophic factors without producing withdrawal signs.
Keywords: aging, nicotine, learning and memory, oxidative stress, mitochondrial dysfunction, neurotrophic factors
INTRODUCTION
In aging, the progressive loss of physiological integrity and the decline of functional capacity lead
to a range of disabilities. The cardinal aspects of aging of the brain include cognitive impairment,
anxiety and depression. Oxidative stress, mitochondrial damage, apoptosis, neurotrophic factor
loss, and cholinergic system dysfunction are known to be associated with aging of the brain
and age-related deficits of learning and memory (Paradies et al., 2011; Gleichmann et al., 2012;
Guarente, 2014; Ali et al., 2015; Richter et al., 2017). Multiple strategies have been tested with
the goal of attenuating dysfunction of the aging brain, including the use of neuroprotective
agents (He et al., 2009), inhibition of neuroinflammatory processes, prevention of oxidative stress
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(Zhang et al., 2009; Lu et al., 2010b; Ali et al., 2015) and activation
of cholinergic neurotransmission (Lu et al., 2010b).
Nicotine is a nAChR agonist and pharmacological chaperone
that stimulates cholinergic activity in the brain (Jackson et al.,
2010; Sadigh-Eteghad et al., 2015a). It has been shown that
nicotine improves working memory, executive function, and
cognitive performance, both in human and animals (Rushforth
et al., 2011; Jansari et al., 2013; Vafaee et al., 2015; Majdi
et al., 2017). Nicotine also reduces reactive oxygen species (ROS)
generation by brain mitochondria and prevents oxidative stress
in a dose-dependent manner (Cormier et al., 2003; Guan et al.,
2003). Nicotine further protects neurons against mitochondrial
apoptosis (Garrido et al., 2001). There is evidence that nicotine
is neuroprotective and regulates neurotrophic factors in the
brain and that it affects the development and maturation of
neurons (Xiaoyu, 2015). Experimental and clinical studies both,
have revealed that nicotine administartion renders pro-cognitive
effects (Bontempi et al., 2003;Myers et al., 2008). This finding has
implications in the treatment of disorders which primarily affect
cognition including Alzheimer’s disease (AD; Levin et al., 2006).
Nonetheless, it is clear that nicotine may induce dependency
and subsequent withdrawal symptoms in animals and humans
that can be prevented by use of limited doses and selective
routes of delivery to the brain (Matta et al., 2007). Intranasal
(i.n.) drug delivery is one such alternative to conventional routes
of administration to the brain. The delivery is non-invasive,
bypasses blood-brain barrier (BBB), allowing the drug to target
the olfactory region as the direct avenue from nose to the brain.
In the case of nicotine, the intranasal route is an alternative choice
for delivery of nicotine to the brain (Farzampour et al., 2016;
Pourmemar et al., 2017).
Chronic administration of D-galactose (DGal) to animals has
consequences that mimic the characteristics of the aging brain
and the related learning and memory impairment in humans
(Kumar et al., 2010; Lu et al., 2010a; Lan et al., 2012; Tsai and
Yin, 2012; Salehpour et al., 2017), with extensive application of
this animal model to the study of the aging brain (Wei et al.,
2005; Hsieh et al., 2009; Lu et al., 2010b; Zhou et al., 2013; Ali
et al., 2015; Sadigh-Eteghad et al., 2017). It has been reported that
DGal administration could recapulate the changes that happen
during accelerated aging (Song et al., 1999). Also, evidence
suggests that prolonged DGal-injected animals resemble their
16- to 24-month-old senescent animals (Gong and Xu, 1991;
Li et al., 1995; Zhang et al., 1996). These characteristics make
DGal-induced aging model a valid tool to recapitulate human
aging in rodent (Song et al., 1999).
Here, we tested the claim that chronic nicotine administration
attenuates memory impairment, apoptosis, and oxidative
damage by cholinergic receptor activation, and that it may raise
neurotrophic factors, independently of its addictive potential in
a mouse model of aging of the brain induced by DGal.
MATERIALS AND METHODS
Animals
Seventy-two male BALB/c mice weighing 25–30 g were
obtained from Tabriz University of Medical Sciences laboratory
animal care center. Animals were socially housed in standard
polypropylene cages (five in each cage) under the controlled
condition of constant humidity and temperature on a 12 h
light/12 h dark schedule before and through study with access
to water and standard pellet food ad libitum.
Ethics Statement
All efforts were made to minimize animal suffering and the
number of animals used. Also, all procedures were performed
in accordance with the recommendations of the guide for the
care and use of laboratory animals of the National Institutes of
Health (NIH; Publication No. 85-23, revised 1985) and approved
by the regional ethics committee of Tabriz University of Medical
Sciences (IR.TBZMED.REC.1395.61).
Experimental Procedures
The animals were randomly divided into six groups with
12 mice in each; in the control group, mice did not receive
any injection or treatment. In the DGal-induced aging group,
for modeling of brain aging, mice were injected with DGal
(500 mg/kg s.c. for 6 weeks; Sigma-Aldrich, St. Louis, MO,
USA). Separate groups of DGal-injected mice received either NS
or nicotine (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
through either s.c. (0.1, 0.5 and 1 mg/kg) or i.n. (0.1 mg/kg)
routes for 6 weeks. For i.n. administration of nicotine drops
containing 5–6 µl were administered through nasal mucosa with
alternation between left and right nares for 2 min to reach the
total desired volume (Pourmemar et al., 2017). At the end of
the treatment administration period, the behavioral tests and
biochemical analyses were performed (Figure 1). All tests were
performed by an experimenter that was unaware of the identity
of experimentations. All solutions were freshly prepared on the
day of experimentation by dissolving drugs in NS (0.9% NaCl).
All injections had a volume of 8 ml/kg body weight.
Withdrawal Signs Assessment
Twenty-four hours after the administration of the last dose of
treatments, the withdrawal signs of mice was assessed using the
following tests (Damaj et al., 2003).
Somatic Signs
Mice were placed in the Plexiglas cages, and their behavior was
recorded and controlled for somatic withdrawal signs including
paw tremors, head shakes, writhing, retropulsion, scratching and
Straub tail for 20 min.
Elevated Plus-Maze
To assess animals’ anxiety, elevated plus-maze (EPM) test was
used. Briefly, EPM consisted of two open and two fenced arms
that stretched from a central platform raised 60 cm from the
ground. Mice were placed in the center of the maze, their
behavior was recorded for 5 min and analyzed using EthoVision
video tracking system, and the percentage of time spent in the
open arms (%OAT) and entries to the open arms (%OAE)
were extracted. After each animal removal, the apparatus was
completely cleaned with a 70% ethanol to remove olfactory or
intra-apparatus cues.
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FIGURE 1 | The experimental design and timescale of the study.
Open Field Test
Mice locomotor activity and anxiety were evaluated using open
field test. The animals were placed in a black Plexiglas open-field
box measuring 33 cm × 33 cm × 20 cm and their behavior was
recorded using EthoVision video tracking system for 20 min.
The total distance moved considered as a locomotor activity, and
arena periphery locomotion was measured as anxiety index.
Thermal Hyperalgesia
The hotplate test was used to assess animals’ thermal
hyperalgesia. The animal was placed in a cylindrical glass
(width: 20 cm) on a hot plate apparatus, and the temperature
maintained at 48◦C. The reaction time for paw-licking or
jumping was recorded as indices of thermal hyperalgesia.
Learning and Memory Profile
Novel Object Recognition
Novel object recognition (NOR) test was used to assess
mice recognition memory. It was performed according to the
previously explained method (Pourmemar et al., 2017). Briefly,
the test apparatus was a black Plexiglas open-field box measuring
33 cm × 33 cm × 20 cm. One day before the training session,
mice were placed in the test room for 15 min for acclimation,
and then each animal was transferred to the test box for a 10-min
habituation session. On the training session, two identical objects
(A and A’) were placed in the box and introduced to the mice.
The objects used were common and different in shape and
texture, however, were counterbalanced in complexity. Then,
each animal was placed in themiddle of the box and the total time
spent to explore each object was recorded over 10 min. The mice
then returned to their home cage. The next day after training
session mice were reintroduced to the same task, but one of the
familiar objects applied during the training session was replaced
by a novel object (B) for a single retention session. The mice were
considered to be exploring when the animal nose was toward the
object (a distance of ≤2 cm), and there was rearing up against
it. After each trial, the test box and objects were cleaned with a
70% ethanol to eliminate the presence of any olfactory cues. The
cut-off time for exploration of two objects was 20 s over a period
of 10 min. The recognition memory was measured by the time
spent exploring of novel object. Data were acquired using a video
camera that was fixed above the center of the task apparatus and
analyzed using a video tracking program Etho VisionTM (Noldus,
Netherlands).
Barnes Maze
The Barnes maze was used to assess spatial learning and memory
in the animals (Sunyer et al., 2007). The maze consisted of a
circular platform 100 cm in diameter raised 50 cm from the
ground, with 20 holes (hole diameter: 5 cm) around the maze.
An escape box (20 cm × 15 cm × 5 cm) was placed under the
target hole. The test was carried out in a room with special spatial
cues located on the walls and a buzzer (80 dB) as a negative
stimulus.
The Barnes maze test included habituation, acquisition and
probe sessions lasting 6 days. The first day of the test comprised
habituation session. During this session, the animal was located
in the center of the maze in a black cylindrical start chamber.
After 10 s, the start chamber was lifted, the buzzer was switched
on, and the animal was gently guided to the escape box, the
buzzer was turned off, and the mice stayed there for 1 min.
The consequent days consisted of four acquisition trials per
day, divided by a 3-min interval for 4 days. In the spatial
acquisition session, the same condition repeated and animals
were free to explore arena and find the escape box for 3 min.
After entering the box, the buzzer was turned off, and the
mice remained there for 1 min. The last day of the experiment
had one probe trial session lasting 3 min. The Barnes maze
arena without the escape box was used to assess mice reference
memory.
After each session and trial, the entire maze and escape box
were cleaned with 70% alcohol to remove olfactory cues. The
time that took the mice to find the escape box (latency time)
during the training sessions, time spent in the target quadrant,
and correct to error time (time spent in the target hole/time spent
in the error holes) during the probe session were evaluated using
EthoVisionTM software.
Oxidative Damage to Mitochondria
Brain Tissue Sampling and Isolation of Mitochondria
Twenty-four hours after the last behavioral test, mice were
decapitated after deep anesthesia with ketamine (100 mg/kg)
and xylazine (10 mg/kg). The animal brain except cerebellum
was then extracted and transferred to the freezing beaker for
further evaluations and biochemical assays. For mitochondria
isolation, fresh brain samples placed in ice-cold isolation
buffer containing 200-mM mannitol, 70-mM sucrose, 10-mM
HEPES, and 2-mM EDTA, pH 7.5. Thereafter, the tissue was
homogenized in ice-cold extraction buffer having 2 mg/mL
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albumin (10% w/v). The samples were centrifuged at 600 g
in 4◦C for 5 min. Then, the supernatant was transferred into
another tube and centrifuged at 12,000 g in 4◦C for 15 min.
Finally, the pellet was resuspended in storage buffer containing
10-mM HEPES, pH 7.4, 250-mM sucrose, 1-mM ATP, 0.08-mM
ADP, 5-mM sodium succinate, 2-mM K2HPO4 and 1-mMDTT.
Protein level was determined by Bradford method (Bradford,
1976).
Mitochondrial Membrane Potentials
Mitochondrial membrane potentials (MMP) or ∆ψm changes
were detected using JC-1 vital dye (Mitochondria Staining Kit;
Sigma-Aldrich, St. Louis, MO, USA). Under normal condition,
the concentration of dye in the mitochondrial matrix produces
red fluorescent. Any situation during which the MMP is
dissipated results in shifting from red to green fluorescence
responsible for J-aggregates and JC-1 monomers respectively.
Briefly according to the kit instructions, JC-1 stain (0.6 µM) was
used. Fluorescence intensity in the stained samples was measured
by the fluorimetric assay. The ratio of red (λex = 490 nm,
λem = 590 nm) to green (λex = 488 nm, λem = 530 nm)
fluorescence intensity was considered as the ∆ψm which was
normalized to the sample proteins.
Mitochondrial ROS Generation
To determine the mitochondrial ROS level, the fluorescent
vital dye dichlorohydro-fluorescein diacetate (DCFDA) was
used (Novalija et al., 2003). This fluorescent probe (2-µM
at 37◦C for 20 min) is oxidized by mitochondrial ROS
to Dichlorodihydrofluorescein (DCF), and the resulting
fluorescence intensity was measured according to the DCF
spectral characteristics (λex = 485 nm, λem = 530 nm). The
resulting ROS level was expressed as fluorescence intensity
which was normalized to the sample proteins.
Apoptosis Markers and Cytochrome C
Western blotting was performed using the previously explained
method (Sadigh-Eteghad et al., 2015b). For total and cytosolic
fractions preparations, 100 mg of fresh brain tissue was
homogenized using ice-cold mitochondria isolation buffer
[200 mM mannitol, 80 mM HEPES-KOH (pH 7.4), and the
protease inhibitor cocktail]. Homogenates were centrifuged at
750× for 10 min at 4◦C. After removing half of the supernatants
that were used as total fractions, the rest of the supernatants
were centrifuged at 12,000× g for 20 min at 4◦C which was the
mitochondria free fraction including cytosol.
Radioimmunoprecipitation assay (RIPA) buffer containing
protease inhibitors plus total or cytosolic fractions were
homogenized. The protein concentration of the sample
was determined using the Bradford assay (Li et al., 2008).
Electrophoresis was performed using 12.5% polyacrylamide gel,
and the isolated proteins were transferred onto a polyvinylidene
difluoride (PVDF; Roche, United Kingdom). These membranes
were then incubated with the primary antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) including anti-caspase-3
(1:500, sc-7148), anti-Bcl-2 (1:500, sc-492), anti-Bax (1:500,
sc-493), and anti-cytochrome C (1:500, sc-7159) antibodies.
After three times of washing lasting 5 min each, the membranes
were incubated with the horseradish peroxidase conjugated
goat anti-rabbit IgG secondary antibody for 60 min (1:5000,
sc-2004). The membranes were finally positioned in ECL
prime western blotting detection reagent (Amersham, United
Kingdom) and the resulting signals visualization was achieved
using Kodak autoradiography film (Kodak, Rochester, NY,
USA). Anti β-actin (1:500, sc-130656) antibody was applied
for internal control of the procedure. The quantification
of the signal intensity of each band was performed using
ImageJ 1.62 software (National Institutes of Health, Bethesda,
MD, USA) and was normalized to the matching internal
control.
Brain BDNF and NGF
ELISAmethod was used to determine mouse BDNF (Elabscience
Biotechnology, China) and brain NGF (Shanghai Crystal day
Biotech, China) levels in the brain homogenate. All procedures
and calculations were performed using a commercial kit
according to the manufacturer’s instructions. Briefly, the tissues
were minced to small pieces and rinsed in ice-cold PBS (0.01 M,
pH = 7.4) to eliminate excess blood entirely. Tissue pieces
were weighed and then homogenized in PBS with a glass
homogenizer on ice. To further break the cells, the suspension
was sonicated with an ultrasonic cell disrupter. The homogenates
were then centrifuged for 5 min at 5000× g to get the
supernatant.
Statistics
Descriptive data were expressed as mean ± standard error of
mean (SEM). Comparison of different groups was carried out by
a one-way analysis of variance (ANOVA) followed by the post hoc
Tukey test or two-way ANOVA when applicable. All analyses
were performed using GraphPad Prism software (version 7 for
Windows; GraphPad Software Inc., La Jolla, CA, USA). For all
comparisons, p< 0.05 was considered to be significant.
RESULTS
Withdrawal Signs
Somatic Signs
One-way ANOVA showed a statistically significant difference
between groups in the somatic signs presented by the animals
(F(5,66) = 18.55, p < 0.001). Post hoc analysis revealed that
spontaneous withdrawal of nicotine had not a significant impact
on the number of somatic signs at the administered doses
except for 1 mg/kg s.c. dose which significantly increased the
number of somatic signs compared to other groups (p < 0.01;
Figure 2A).
Elevated Plus Maze
We found statistically significant differences between
groups in OAT (F(5,66) = 11.70, p < 0.001) and OAE
(F(5,66) = 14.05, p < 0.001) tasks in elevated plus maze
(EPM) test. Accordingly, post hoc analysis showed that
chronic DGal+NS administration reduced both OAT and
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FIGURE 2 | Withdrawal signs in study groups. (A) Number of somatic signs, (B) percentage of time spent in the open arms of EPM, (C) percentage of entries to the
open arms of EPM, (D) locomotor activity, (E) distance moved in the center of the arena and (F) hotplate latency times. Each bar represents the mean ± standard
error of mean (SEM), (n = 12). Significant differences tested by one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test; ∗p < 0.05 and ∗∗p < 0.01
compared to the control group. #p < 0.05 and ##p < 0.01 compared to the DG+NS group; NS, normal saline; DG, D-galactose; Nic, nicotine; s.c., subcutaneous;
i.n., intranasal; EPM, elevated plus maze.
OAE in comparison to the control group (p < 0.05). On
the other hand, chronic nicotine injection increased OAT at
0.5 mg/kg s.c. dose in DGal-received animals. Also, chronic
nicotine administration at 1 mg/kg s.c. dose significantly
decreased OAT and OAE compared with the DGal+NS group
(p < 0.05 and p < 0.01 respectively). Other used doses of
nicotine did not significantly affect OAT and OAE (p > 0.05;
Figures 2B,C).
Open Filed Test
There was no significant difference between groups in the total
distance moved in open filed test (F(5,66) = 1.824, p = 0.12;
Figure 2D). However, difference for the time spent in the center
was significant between groups (F(5,66) = 8.206, p < 0.001).
Chronic DGal+NS treatment significantly reduced distance
moved in the center compared to the control group (p < 0.05).
However, chronic nicotine administration at 0.5 mg/kg s.c. and
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0.1 mg/kg i.n. doses remarkably increased distance moved in the
center in comparison to the NS-received DGal group (p < 0.01
and p< 0.05 respectively; Figure 2E).
Hotplate
We found a significant difference between study groups in
hotplate latency time (F(5,66) = 7.766, p < 0.001). Nicotine
administration at 1 mg/kg s.c. dose significantly decreased
latency time in hotplate test in comparison to other groups
(p < 0.01). Other used doses of nicotine did not have an impact
on the hotplate latency time (p> 0.05; Figure 2F).
Learning and Memory Profile
Barnes Maze Test
In the Barnes maze training session, when the mean escape
latency was analyzed across the 4 days of training and treated
groups, a two-way ANOVA revealed significant effects of group
(F(5,264) = 12.38, p < 0.001), day (F(3,264) = 191.7, p < 0.001)
and group-day interaction (F(15,264) = 1.778, p = 0.037). Our
results showed that chronic DGal+NS administration delayed the
finding of escape box in the 3rd and 4th days of the training
session in comparison to the control group (p < 0.05, and
p < 0.01, respectively). Conversely, chronic administration of
nicotine significantly decreased escape latency time on the 3rd
and 4th day of the training session at 0.5 mg/kg s.c. dose (p< 0.05
and p < 0.01 respectively) and on the 4th day at 0.1 mg/kg
i.n. dose compared to the NS-received DGal group (p < 0.01;
Figure 3A).
Also, one-way ANOVA revealed a significant difference in
the time spent in the target quadrant between groups in the
probe session (F(5,66) = 11.331, p < 0.001). Post hoc analysis
showed that chronic injection of DGal+NS remarkably decreased
the time spent in the target quadrant compared to the control
group (p< 0.01). Also, it was shown that chronic administration
of at 0.5 mg/kg s.c. and 0.1 mg/kg i.n. doses significantly
increased the time spent in the target quadrant compared to the
NS-received DGal group (p < 0.01 and p < 0.05 respectively;
Figures 3B,E).
We found a significant difference between groups in mean
relative error time (F(5,66) = 13.465, p < 0.001). We also found
that mean relative error time was significantly lower in the
DGal+NS group in comparison to the control group (p < 0.01).
Chronic nicotine administration increased mean relative error
time at 0.5 mg/kg s.c. and 0.1 mg/kg i.n. doses in comparison to
the NS-received DGal group (p< 0.01 and p< 0.05 respectively;
Figure 3C).
Novel Object Recognition Test
During the training phase, the exploratory preference for
the objects was not influenced by the treatments (Data not
shown; p > 0.05). In the retention phase of NOR test,
analysis showed a significant difference between groups in
the exploratory preference of the animals (F(5,66) = 9.263,
p < 0.001). Chronic DGal+NS injection significantly decreased
the exploratory preference of the animals for the novel object
compared to the control group (p < 0.01). Additionally,
chronic nicotine administration at 0.5 mg/kg s.c. and 0.1 mg/kg
i.n. doses remarkably decreased DGal-induced recognition
memory impairment compared to the DGal+NS -received group
(p< 0.01).
All values were substantially different from the chance
exploration (10 s) in the retention (p < 0.05), but not training
phase (p > 0.05) as illustrated by the dashed line in the
Figure 3D.
Mitochondrial and Apoptotic Profile
We found a significant difference between study groups in
MMP (F(5,42) = 25.164, p < 0.001). A significant decrease in
the MMP was revealed by post hoc analysis in the DGal+NS
group in comparison to the control group (p < 0.01). Also,
treatment with nicotine at 0.5 mg/kg s.c. and 0.1 mg/kg
i.n. doses remarkably increased MMP in comparison to the
NS-received DGal group (p < 0.01 and p < 0.05 respectively;
Figure 4A).
Also, we found a significant difference between groups in
the ROS level, (F(5,42) = 54.811, p < 0.001). Also, chronic
administration of DGal+NS increased ROS level compared to
the control group (p < 0.01). In addition, chronic nicotine
treatment at 0.1 mg/kg i.n. and 0.5 mg/kg s.c. reduced ROS
level in comparison to NS-received DGal group (p < 0.05 and
p< 0.01 respectively; Figure 4B).
Analysis showed a significant difference between groups in
total cytochrome C levels of the brain tissue (F(5,30) = 14.87,
p < 0.001). Chronic administration of DGal+NS decreased
total cytochrome C levels compared to the control group in
the mice brain (p < 0.05). However, chronic administration
of nicotine at 0.1 mg/kg i.n. and 0.5 mg/kg s.c. doses
increased total cytochrome C level in comparison to the
NS-received DGal group (p < 0.05 and p < 0.01 respectively;
Figures 5A,E).
A significant difference was revealed by one-way ANOVA in
cytosolic to total cytochrome C ratio (F(5,30) = 24.34, p < 0.001).
Accordingly, post hoc analysis showed that chronic DGal+NS
administration increases cytosolic to total cytochrome C ratio
in comparison to the control group (p < 0.01). On the other
hand, chronic administration of nicotine at 0.1 mg/kg i.n.
and 0.5 mg/kg s.c. doses decreased this item compared to the
NS-received DGal group (p< 0.01; Figures 5B,E).
We found a significant difference between study groups in
Bax/Bcl-2 ratio (F(5,30) = 149.7, p < 0.001) and caspase-3 levels
(F(5,30) = 133.2, p < 0.001). Subsequently, analysis showed
that chronic DGal+NS injection increased Bax/Bcl-2 ratio and
caspase-3 levels compared to the control group (p < 0.01).
In addition, chronic nicotine treatment at 0.1 mg/kg i.n. and
0.5 mg/kg s.c. doses decreased Bax/Bcl-2 ratio and caspase-3
levels compared to the NS-received DGal group (p < 0.01;
Figures 5C,D,F).
Neurotrophic Factors
We found a significant difference in the BDNF (F(5,42) = 13.24,
p < 0.001) and NGF (F(5,42) = 17.39, p < 0.001) levels in the
brain tissue in study groups. Chronic treatment with DGal+NS
decreased BDNF and NGF levels in comparison to the control
group (p < 0.01). However, chronic nicotine administration at
Frontiers in Aging Neuroscience | www.frontiersin.org 6 July 2018 | Volume 10 | Article 194
Majdi et al. Nicotine Modulates Cognitive Function in Senescence
FIGURE 3 | Learning and memory profile in study groups. (A) Mean escape latency time during 4 days of training session of MWM, (B) mean time spent in the target
quadrant in the probe trial session of MWM, (C) mean relative error time in the probe trial session of MWM, (D) exploration time of the novel object during the
retention session of NOR test, (E) corresponding heat maps show the combined traces of the mice from each group during the probe test of MWM (left lower part
was considered as target quadrant). Values represent the mean ± SEM, (n = 12). Significant differences tested by two- (A) or one-way ANOVA followed by Tukey’s
post hoc test; ∗p < 0.05 and ∗∗p < 0.01 compared to the control group. #p < 0.05 and ##p < 0.01 compared to the DG+NS group; NS, normal saline; DG,
D-galactose; Nic, nicotine; s.c., subcutaneous; i.n., intranasal; MWM, Morris water maze; NOR, novel object recognition.
0.1 mg/kg i.n. and 0.5 mg/kg s.c. doses increased BDNF level
compared to the DGal+NS group (p < 0.01 and p < 0.05;
Figure 6A). Also, chronic nicotine administration at all doses
increased NGF level compared to the NS-received DGal group
(p< 0.01; Figure 6B).
DISCUSSION
Here, we showed that chronic administration of nicotine at doses
of 0.1 mg/kg intranasally and 0.5 mg/kg subcutaneously
decreased cognitive impairment induced by chronic
administration of DGal to mice. We interpret the results as
effects of nicotine against oxidative damage, apoptosis and
neurodegenerative lesions in the mouse brain. Nicotine at these
doses caused no detectable withdrawal signs in the mice. In
contrast, the highest dose of nicotine (1 mg/kg) administered
subcutaneously not only had no positive effects on cognition
or neurochemical factors in brain tissue but also elicited
signs of withdrawal in the treated mice. The lowest dose of
nicotine (0.1 mg/kg) administered subcutaneously, in turn,
had no effects on cognitive function or signs of withdrawal of
the mice.
Age-related memory and learning impairment is thought to
be the result of increased neurodegeneration and decline in the
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FIGURE 4 | Mito-oxidative profile in study groups. (A) Mean of JC-1 red to
green intensity as mitochondrial membrane potential (∆ψm) index, (B) ROS
level, Each bar represents the mean ± SEM, (n = 8). Significant differences
tested by one-way ANOVA followed by Tukey’s post hoc test; ∗∗p < 0.01
compared to the control group. #p < 0.05 and ##p < 0.01 compared to the
DG+NS group; ROS, reactive oxygen species; NS, normal saline; DG, DGal;
Nic, nicotine; s.c., subcutaneous; i.n., intranasal.
neuronal function (Haddadi et al., 2014). The resulting cognitive
decline is a multifactorial process and involves oxidative stress,
altered brain neurotransmitters (Haider et al., 2014), apoptosis
(Kim et al., 2010), mitochondrial dysfunction, et cetera (Martínez
et al., 2000).
The DGal model of brain aging is widely-used in rodent
studies of features of human brain aging (Haider et al., 2015;
Gong et al., 2016; Pourmemar et al., 2017) such as cognitive
function impairment (Lu et al., 2010b; Han et al., 2014). The
Barnes maze task tested the spatial learning and reference
memory associated with hippocampal function in the animals.
The Barnes task is less anxiogenic than other tests that assess
spatial memory (Harrison et al., 2009) and is widely used to assess
cognitive performance in aged animals. Also, the NOR task was
used to assess recognition memory that is linked to connections
between hippocampus and cortex and is impaired during aging
(Gallagher et al., 1993; Sadigh-Eteghad et al., 2015b). These tests
have been formerly used to assess rodent cognitive function in
neurodegenerative disorders such as AD and their responses to
various treatments (O’Leary and Brown, 2009; Sadigh-Eteghad
et al., 2015b).
The results showed that chronic administration of DGal
with NS raised the escape latency time and decreased the
time spent in the target quadrant of the Barnes maze test.
The results indicate impairment of working and reference
memory in the DGal model of aging in mice, in agreement
with results obtained by Ashour et al. (2016). Consistent with
other studies (Wei et al., 2005; Pourmemar et al., 2017), we
found that long-term administration of DGal with NS shortened
explorations of novel object in comparison to the control group,
indicating impairment of recognition memory in NS-treated
DGal mice.
Chronic nicotine treatment at 0.1 mg/kg i.n. and 0.5 mg/kg
s.c. doses reversed the DGal-induced cognitive impairment both
in Barnesmaze andNOR tests. However, nicotine administration
at 0.1 and 1mg/kg s.c. doses did not have a statistically significant
effect on the cognitive performance of the mice in Barnes and
NOR tests. Similarly, in a study by French et al. (2006), it
was revealed that chronic administration of nicotine to aged
rats at 0.1 mg/kg and 0.3 mg/kg doses improved working and
reference memories in Morris water maze (MWM) task. This
study also showed that cognition-improving effect of nicotine
was ‘‘dose-dependent or inverted U shape’’ and certain higher
doses had superior effects on the cognitive function (French
et al., 2006). Another study showed that effects of nicotine on
cognitive function are dependent upon ‘‘duration/magnitude
of nicotine exposure’’ and its procognitive impacts are limited
under specific conditions (Ortega et al., 2013) which may
explain why high (1 mg/kg s.c.) and low (0.1 mg/kg s.c.) doses
used in this study did not have cognition-improving effects
on mice. Similar studies using the same dose of nicotine,
but shorter periods of administration have yielded the same
results in the aged rodent both in MWM and NOR tests
(Socci et al., 1995; Riekkinen and Riekkinen, 1997; Puma et al.,
1999). In a study by Levin and Torry (1996), it was found
that acute nicotine administration reduces cognitive deficits in
aged rats. However, chronic nicotine injection did not have
the same procognitive effects. On the other hand, Arendash
et al. (1995) found that chronic nicotine treatment decreases
learning/memory deficits in aged rats, and the effects were
reproduced in several cognitive tasks. Similarly, Buccafusco and
Jackson (1991) showed that nicotine injection in aged monkeys
improves their performance in delayed matching-to-sample
task.
We could not find any study regarding effects of i.n. nicotine
on the cognitive performance of aged animals. In this study, we
showed that none of the treatments had effect on the locomotor
activity of the mice. These findings were in line with the findings
of previous works (Kalejaiye et al., 2013; Pourmemar et al.,
2017).
The results also revealed that chronic DGal administration
remarkably decreased the number of OAEs in EPM and distance
moved in the center in the open filed test suggesting the
anxiogenic effects of DGal-induced aging on mice. Of direct
relevance to this line of argument is a study by Bessa et al.
(2005), demonstrating that aging is accompanied by increased
signs of anxiety (Torres et al., 2013). Of the administered doses of
nicotine in this study, nicotine at 1 mg/kg s.c. dose significantly
increased withdrawal signs including somatic signs and thermal
hyperalgesia. It also decreased OAE as well as OAT in EPM and
reduced time spent in the arena center in the open field test all
of which indicate nicotine potential to increase withdrawal signs
and induce dependency at this dose. In line with that, a study
by Malin et al. (1992) showed that administration of nicotine at
3 mg/kg dose induced withdrawal signs and thus might cause
dependency inmice. In another study, they stated that 1–3mg/kg
daily dose of nicotine could result in dependency in rodents
(Malin and Goyarzu, 2009). Other nicotine doses used in this
study did not increase withdrawal signs in mice. However, in
a study by Grabus et al. (2005), it was shown that chronic oral
administration of nicotine (∼0.1 mg/kg) increased withdrawal
signs presented by the animal on days 1, 2, 3, but not 5. It is
believed that ‘‘rapid drug delivery’’ and the concentration of the
delivered drug are two main determining factors in the nicotine-
induced dependency (Schneider et al., 1996). So, it appears
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FIGURE 5 | Brain cytochrome C and apoptosis markers levels in different study groups (A) mean total cytochrome C, (B) cytosolic to total cytochrome C level,
(C) mean fold change of Bax to Bcl-2 ratio, (D) mean fold change of caspase-3 levels, (E) representative image of total and cytosolic cytochrome c,
(F) representative image of Bax to Bcl-2 protein and caspase-3. Each bar represents the mean ± SEM, (n = 6). Significant differences tested by one-way ANOVA
followed by Tukey’s post hoc test; ∗p < 0.05 and ∗∗p < 0.01 compared to the control group; #p < 0.05 and ##p < 0.01 compared to the DG+NS group; NS, normal
saline; DG, D-galactose; Nic, nicotine; s.c., subcutaneous; i.n., intranasal.
that the administered doses of nicotine in this study (except
1mg/kg s.c.) due to the specific rate of delivery and concentration
of nicotine in the brain did not produce withdrawal signs in
mice.
Our data demonstrated that chronically administered DGal
increases ROS levels in the mice brain. In line with that many
studies have found that chronic DGal administration increases
ROS levels and causes oxidative stress in the brain (He et al., 2009;
Kumar et al., 2010; Hao et al., 2014) which then predisposes the
brain to neurodegeneration and aging (Floyd and Hensley, 2002;
Majdi et al., 2016).
We also showed that chronic nicotine administration at
0.1 mg/kg i.n. and 0.5 mg/kg s.c. doses significantly reduced
brain ROS levels in mice. In a study by Linert et al. (1999),
the authors concluded that nicotine at 0.8 mg/kg i.p. dose does
not change ROS levels in the brain. They also stated that the
anti-oxidant properties of nicotine might be mediated through
its blocking effects on Fenton’s reaction. Also, it has been shown
that nicotine may have dual effects on oxidative stress and ROS
formation in the brain depending upon the administered dose. It
is believed that nicotine has ‘‘inverted U-shaped dose-response
curves’’ meaning high doses increase oxidative stress whereas
medium doses show antioxidant properties (Guan et al., 2003).
MMP perturbations may have a role in the progression
of aging (Reddy and Beal, 2008). Similar to the Shen et al.
(2014) results, the findings of the present study showed that
chronic DGal administration decreases MMP and thus increases
mito-oxidative damage. It is believed that decrease in the
MMP increases mitochondrial permeability which subsequently
increases ROS and cytochrome C release from mitochondria
and results in apoptosis as well as neuronal death (Pollack and
Leeuwenburgh, 2001; Zhang et al., 2010). Evidence suggests
that ROS formation does not occur until MMP changes which
proves MMP importance in the DGal-induced mito-oxidative
stress (Nohl et al., 2005). Conversely, some studies have found
that increase in the ROS levels causes mitochondrial membrane
anisotropy and apoptosis. In fact, increased oxidative stress
and ROS levels causes MMP collapse, and transient ROS
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FIGURE 6 | Neurotrophic factors level in study groups. (A) BDNF and (B) NGF
level in different groups. Each bar represents the mean ± SEM, (n = 8).
Significant differences tested by one-way ANOVA followed by Tukey’s
post hoc test; ∗∗p < 0.01 compared to the control group, #p < 0.05 and
##p < 0.01 compared to the DG+NS group; BDNF, brain-derived neurotrophic
factor; NGF, nerve growth factor; NS, normal saline; DG, D-galactose; Nic,
nicotine; s.c., subcutaneous; i.n., intranasal.
release to the cytosol which triggers ROS reproduction and
is called ‘‘ROS-induced ROS-release’’ (Zorov et al., 2006).
We found that chronic nicotine administration at 0.1 mg/kg
i.n. and 0.5 mg/kg s.c. doses reduce mito-oxidative damage
through decreasing mitochondrial membrane anisotropy. In
line with that Cormier et al. (2003), reported that chronically
administered nicotine at 0.6 mg/kg dose had protective effects
on mitochondria and prevented mitochondrial membrane
anisotropy and mito-oxidative damage which happens in
neurodegeneration and aging (Cormier et al., 2003; Reddy and
Beal, 2008).
In this study, we also showed that chronic injection of DGal
increases cytoplasmic to total cytochrome C ratio and decreases
total cytochrome C levels in the brain. It also increased Bax/Bcl-
2 ratio and caspase-3 levels in DGal-received mice brain. As
we discussed earlier DGal treatment increases ROS levels in
the brain which leads to MMP perturbations. This subsequently
increases cytochrome C release to the cytoplasm. Cytoplasmic
cytochrome C then links to other apoptotic factors and
creates an apoptosome which then activates caspase-3 (Pollack
and Leeuwenburgh, 2001; Pollack et al., 2002). In addition,
DGal-induced increase in the Bax/Bcl-2 ratio further increase
cytochrome C release to the cytoplasm and exacerbates the
above-mentioned pathologic pathway. These mechanisms finally
result in neuronal apoptosis as an important component of brain
aging and neurodegeneration (Beal, 2005). DGal administration
also decreased total cytochrome C levels which may indicate
an age-related decrease in the number of active mitochondria
(Navarro et al., 2002; O’Toole et al., 2010).
In this study, administration of nicotine at 0.5 mg/kg s.c.
and 0.1 mg/kg i.n. doses was found to reverse the mentioned
pathologic events. Nicotine decreased Bax/Bcl-2 ratio as well as
cytochromeC release to the cytoplasm. This along with decreased
caspase-3 levels is thought to prevent the subsequent apoptosis
in the DGal-received mice brain. In line with that, nicotine has
been shown to be the so-called ‘‘survival agonist’’ and inhibit
pro-apoptotic pathways (Mai et al., 2003; Tizabi et al., 2005). In a
direct relevance to this line of evidence, Marrero and Bencherif
(2009) showed that nicotine increases the production of Bcl-2
and blocks the release of cytochrome C the cytosol and prevents
apoptosis. Nicotine at the mentioned doses also increased total
cytochrome C levels suggesting nicotine-induced improvement
of mitochondrial function.
We confirmed that long-term DGal injection reduces NGF
and BDNF levels as neuroprotective factors in the brain.
Woo et al. (2014) found that chronic DGal administration
impairs neurotrophic factors production in the brain resulting in
cognitive impairment. Similarly, Erraji-Benchekroun et al. (2005)
showed that the production of neurotrophic factors declines
through time in the aging brain. The results of this study
also showed that nicotine treatment chronically at 0.5 mg/kg
s.c. and 0.1 mg/kg i.n. doses can increase BDNF levels in the
DGal-received mice brain. Also, all the administered doses of
nicotine increased NGF level in this aging model.
Nicotine-mediated enhancement of nuclear translocation and
transcriptional activity of NF-κB amplifies the expression of NGF
and protects the brain from aging-induced neuronal damage
(Wongtrakool et al., 2014). Additionally, nicotine regulates NGF
level possibly via glutamatergic neurones modulation (Rattray,
2001). The increased NGF levels in the brain could then
improve learning, memory and cognitive performance (Fischer
et al., 1991; De Rosa et al., 2005) which is impaired in aging.
Also, evidence suggests that chronic nicotine administration at
0.5 mg/kg i.p. dose (Kenny et al., 2000) increases expression
of BDNF through α7 nAChRs-mediated pathways. BDNF
then involves in memory formation in the hippocampus and
long-term potentiation (Tyler et al., 2002; Czubak et al., 2009).
Intranasal drug delivery is a novel and safe way to administer
medications through the nasal mucosa (Farzampour et al.,
2016). This route of drug administration shunts the BBB, is
non-invasive and encompasses two separate pathways including
trans-neuronal or immediate and para-neuronal or delayed
(Mustafa et al., 2016). It has been shown that nicotine
nasal spray improves continuous attention, working memory,
and executing processing (Smith et al., 2002; Myers et al.,
2008). Our results suggested the anti-aging effect of intranasal
nicotine on mice through its anti-apoptosis, neuroprotective
and anti mito-oxidative actions without increasing withdrawal
signs presentation and causing dependency. This might be an
alternative approach in the treatment of age-associated cognitive
impairment.
In conclusion, this set of data showed that nicotine at
certain controlled doses has a potential to attenuate age-induced
cognitive impairment without producing withdrawal signs and
dependency. These doses could also ameliorate age-induced
mito-oxidative damage, apoptosis and neurotrophic factors
level reduction. Further, our results indicated that i.n. nicotine
delivery could be an alternative choice for the treatment of
age-related cognitive decline.
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